



**PUBLICATION OF A TRANSPARENCY NOTIFICATION RECEIVED BY MITHRA
PHARMACEUTICALS SA/NV**

Liège, Belgium, 24 November 2017 – Regulated Information – Mithra Pharmaceuticals SA/NV (Euronext Brussels: MITRA) today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from OGEO Fund OFP and from OGESIP Invest SA, an investment company controlled by OGEO Fund.

OGEO Fund has notified Mithra that it has dropped below the 3% threshold on 21 November 2017 and now holds 0% of the 34,242,731 shares currently outstanding. According to the last transparency notification received by Mithra, OGEO Fund previously held 4.33% of outstanding shares (1,481,700 shares).

As a result of a transfer of shares from OGEO Fund to OGESIP Invest SA, OGESIP Invest SA now holds 3.45% of outstanding shares (1,181,700 shares), and hence crossed the reporting threshold of 3% on 21 November 2017.

The detailed transparency notifications are available on the [Investors website](#) of Mithra (investors.mithra.com). An updated overview of the Mithra’s large shareholdings will be included in the corporate governance charter of Mithra, which will be made available on its website.

For more information, please contact:

Investor Relations

Sofie Van Gijssel, IRO
+32 485 19 14 15
investorrelations@mithra.com
svangijssel@mithra.com

Press

Julie Dessart
Chief Communication Officer
+32 4 349 28 22 / +32 475 86 41 75
press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO.

Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's mailing list, visit investors.mithra.com